Patents by Inventor Yuki Taga
Yuki Taga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109842Abstract: Provided is an acrylamide compound, which is useful for the promotion of platelet production from platelet progenitor cells such as megakaryocytes in vitro and represented by general formula [I]: wherein each symbol is as defined in the description.Type: ApplicationFiled: December 8, 2020Publication date: April 4, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hideki HAYASHI, Ryosuke TAGA, Yuki SAKAMOTO, Nozomi KUWANO, Kurumi MINENO, Kazuhiro OHDACHI, Yusuke FUJIMORI
-
Patent number: 11932657Abstract: Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1, R2, R3, R4, n, and X are as defined above, or a salt thereof.Type: GrantFiled: September 6, 2019Date of Patent: March 19, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kazuhiro Ohdachi, Yusuke Fujimori, Naoya Makita, Noritaka Koseki, Hideki Hayashi, Yuki Sakamoto, Kurumi Mineno, Ryosuke Taga
-
Patent number: 10925962Abstract: Provided are: a polymeric IgA-type recombinant antibody; a medicine containing this polymeric IgA-type recombinant antibody as an active ingredient; a method for producing this polymeric IgA type antibody, the method including the step of coexpressing an IgA-type antibody heavy-chain protein, an antibody light-chain protein, an antibody J-chain protein, and a secretory component protein within a single cell; and a method for improving the antigen-binding activity or neutralizing activity of this antibody, the method including the step of making an antibody into a polymeric IgA-type.Type: GrantFiled: July 21, 2015Date of Patent: February 23, 2021Assignee: Nippi, IncorporatedInventors: Shinji Saito, Tadaki Suzuki, Hideki Hasegawa, Akira Ainai, Kiyoko Goto, Tomonori Ueno, Yuki Taga
-
Patent number: 10442843Abstract: It has been believed that promoting the assembly of polysomes composed of many ribosomes attached to mRNA is very effective for highly efficient protein synthesis. However, the mechanism for p180 protein's capability of promoting polysome formation has been yet to be elucidated. The inventors of the present application newly discovered SF3b4 protein as a protein that specifically interacts with the coiled-coil domain of p180 protein, a responsible region for its capability of promoting polysome formation, and which is capable of promoting mRNA localization to an endoplasmic reticulum (ER). The inventors also found that, in cells capable of highly expressing both p180 protein and a protein promoting mRNA localization to an endoplasmic reticulum (ER) (e.g., SF3b4 protein), the mRNA localization to the endoplasmic reticulum can be significantly elevated so that the secretory capacity in cultured cells can be enhanced.Type: GrantFiled: August 24, 2017Date of Patent: October 15, 2019Assignee: NIPPI, INCORPORATEDInventors: Tomonori Ueno, Yuki Taga, Kiyoko Goto, Yuko Kaku
-
Publication number: 20180118796Abstract: It has been believed that promoting the assembly of polysomes composed of many ribosomes attached to mRNA is very effective for highly efficient protein synthesis. However, the mechanism for p180 protein's capability of promoting polysome formation has been yet to be elucidated. The inventors of the present application newly discovered SF3b4 protein as a protein that specifically interacts with the coiled-coil domain of p180 protein, a responsible region for its capability of promoting polysome formation, and which is capable of promoting mRNA localization to an endoplasmic reticulum (ER). The inventors also found that, in cells capable of highly expressing both p180 protein and a protein promoting mRNA localization to an endoplasmic reticulum (ER) (e.g., SF3b4 protein), the mRNA localization to the endoplasmic reticulum can be significantly elevated so that the secretory capacity in cultured cells can be enhanced.Type: ApplicationFiled: August 24, 2017Publication date: May 3, 2018Inventors: Tomonori UENO, Yuki TAGA, Kiyoko GOTO, Yuko KAKU
-
Patent number: 9884897Abstract: It has been believed that promoting the assembly of polysomes composed of many ribosomes attached to mRNA is very effective for highly efficient protein synthesis. However, the mechanism for p180 protein's capability of promoting polysome formation has been yet to be elucidated. The inventors of the present application newly discovered SF3b4 protein as a protein that specifically interacts with the coiled-coil domain of p180 protein, a responsible region for its capability of promoting polysome formation, and which is capable of promoting mRNA localization to an endoplasmic reticulum (ER). The inventors also found that, in cells capable of highly expressing both p180 protein and a protein promoting mRNA localization to an endoplasmic reticulum (ER) (e.g., SF3b4 protein), the mRNA localization to the endoplasmic reticulum can be significantly elevated so that the secretory capacity in cultured cells can be enhanced.Type: GrantFiled: March 26, 2014Date of Patent: February 6, 2018Assignee: NIPPI, INCORPORATEDInventors: Tomonori Ueno, Yuki Taga, Kiyoko Goto, Yuko Kaku
-
Publication number: 20170340732Abstract: Provided are: a polymeric IgA-type recombinant antibody; a medicine containing this polymeric IgA-type recombinant antibody as an active ingredient; a method for producing this polymeric IgA type antibody, the method including the step of coexpressing an IgA-type antibody heavy-chain protein, an antibody light-chain protein, an antibody J-chain protein, and a secretory component protein within a single cell; and a method for improving the antigen-binding activity or neutralizing activity of this antibody, the method including the step of making an antibody into a polymeric IgA-type.Type: ApplicationFiled: July 21, 2015Publication date: November 30, 2017Inventors: Shinji Saito, Tadaki Suzuki, Hideki Hasegawa, Akira Ainai, Kiyoko Goto, Tomonori Ueno, Yuki Taga
-
Patent number: 9486491Abstract: Provided are methods of producing a novel collagen peptide composition, and a DPP-4 inhibitor and antihyperglycemics that comprise the above-mentioned collagen peptide composition. Ginger rhizome-derived enzymes are added to and break down a collagen and/or gelatin solution to generate peptide compositions comprising peptides represented by X-Hyp-Gly (wherein X represents an amino acid residue other than Gly, Hyp, and Pro). The thus obtained collagen peptide composition has a high DPP-4 inhibitory activity and an excellent antihyperglycemic effect.Type: GrantFiled: July 23, 2013Date of Patent: November 8, 2016Assignee: Nippi, IncorporatedInventors: Yuki Taga, Masashi Kusubata, Satoshi Suzuki, Osamu Hayashida, Yoh-ichi Koyama, Shunji Hattori
-
Patent number: 9340579Abstract: A DPP-4 inhibitor comprising a peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (SEQ ID NO: 16) (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; 5 Xb is Gly, Pro, or deletion; Xc is Pro, Ala, or deletion; and Xd is an amino acid residue or deletion) as an active component. The inhibitor can be expected to bring out an effect of lowering blood glucose levels by enhancing effects of incretins; and the inhibitor may be used as a therapeutic agent for diabetes and, in addition, can act on the immune system or the like to be thus used in 10 treatment for skin diseases or the like.Type: GrantFiled: November 2, 2012Date of Patent: May 17, 2016Assignee: NIPPI, INCORPORATEDInventors: Osamu Hayashida, Masashi Kusubata, Yuji Atsuzawa, Yuki Taga, Youichi Koyama, Shunji Hattori
-
Publication number: 20160075747Abstract: It has been believed that promoting the assembly of polysomes composed of many ribosomes attached to mRNA is very effective for highly efficient protein synthesis. However, the mechanism for p180 protein's capability of promoting polysome formation has been yet to be elucidated. The inventors of the present application newly discovered SF3b4 protein as a protein that specifically interacts with the coiled-coil domain of p180 protein, a responsible region for its capability of promoting polysome formation, and which is capable of promoting mRNA localization to an endoplasmic reticulum (ER). The inventors also found that, in cells capable of highly expressing both p180 protein and a protein promoting mRNA localization to an endoplasmic reticulum (ER) (e.g., SF3b4 protein), the mRNA localization to the endoplasmic reticulum can be significantly elevated so that the secretory capacity in cultured cells can be enhanced.Type: ApplicationFiled: March 26, 2014Publication date: March 17, 2016Inventors: Tomonori Ueno, Yuki Taga, Kiyoko Goto, Yuko Kaku
-
Publication number: 20150182580Abstract: Provided are methods of producing a novel collagen peptide composition, and a DPP-4 inhibitor and antihyperglycemics that comprise the above-mentioned collagen peptide composition. Ginger rhizome-derived enzymes are added to and break down a collagen and/or gelatin solution to generate peptide compositions comprising peptides represented by X-Hyp-Gly (wherein X represents an amino acid residue other than Gly, Hyp, and Pro). The thus obtained collagen peptide composition has a high DPP-4 inhibitory activity and an excellent antihyperglycemic effect.Type: ApplicationFiled: July 23, 2013Publication date: July 2, 2015Applicant: Nippi, IncorporatedInventors: Yuki Taga, Masashi Kusubata, Satoshi Suzuki, Osamu Hayashida, Yoh-ichi Koyama, Shunji Hattori
-
Publication number: 20140309401Abstract: A DPP-4 inhibitor comprising a peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; Xb is Gly, Pro, or deletion; Xc is Pro, Ala, or deletion; and Xd is an amino acid residue or deletion) as an active component. The inhibitor can be expected to bring out an effect of lowering blood glucose levels by enhancing effects of incretins; and the inhibitor may be used as a therapeutic agent for diabetes and, in addition, can act on the immune system or the like to be thus used in treatment for skin diseases or the like.Type: ApplicationFiled: November 2, 2012Publication date: October 16, 2014Inventors: Osamu Hayashida, Masashi Kusubata, Yuji Atsuzawa, Yuki Taga, Youichi Koyama, Shunji Hattori